Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone

Head and Neck

Volumn 35, Issue 2, 2013, Pages

  Caballero, Miguel ^a   Sosa, Aaron E ^a   Tagliapietra, Andrea ^a   Grau, Juan J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

adenoid cystic carcinoma; cetuximab; chemoresistance; metronomic schedule; paclitaxel

Indexed keywords

CETUXIMAB; PACLITAXEL;

ADENOID CYSTIC CARCINOMA; ADULT; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; ERYTHEMA; FOLLICULITIS; HUMAN; LUNG METASTASIS; MALE; METRONOMIC DRUG ADMINISTRATION; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SUBMANDIBULAR GLAND; TRANSTHORACIC ASPIRATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARCINOMA, ADENOID CYSTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SALIVARY GLAND NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84872803850     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21870     Document Type: Conference Paper

References (18)

1. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP,. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114; 806-816.
2. Bradley PJ,. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg 2004; 12: 127-132.
3. Dodd RL, Slevin NJ,. Salivary gland adenoid cystic carcinoma: a review of chemoteraphy and molecular therapies. Oral Oncology 2006; 42: 759-769.
4. Kaplan MJ, Johns ME, Cantrell RW,. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 1986; 95: 165-170.
5. Belani CP,. Preliminary experience with chemotherapy in advanced salivary glands neoplasms. Med Pediat Oncol 1988; 16: 197-202.
6. Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma: a phase II trial of 22 patients. Ann Oncol 1996; 7: 640-642.
7. Vered M, Braunstein E, Buchner A,. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002; 24: 632-636.
8. Till BG, Martins RG,. Response to paclitaxel in adenoid cystic carcinoma of the salivary glands. Head Neck 2008; 30: 810-814.
9. Visa L, Caballero M, Grau JJ,. Response to metronomic chemotherapy in a metastatic adenoid cystic carcinoma of the parotid gland. Acta Otorrinolaringol Esp 2010; 61: 452-454.
10. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006; 28: 197-204.
11. Caballero M, Grau JJ, Blanch JL, et al. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2007; 133: 1143-1148.
12. Holsinger FC, Doan DD, Jasser SA, et al. Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clinic Cancer Res 2004; 10: 794-801.
13. Morelli MP, Cascone T, Troiani T, et al. Sequence dependent antiproliferative effects of citotoxic drugs and epidermal growth factor receptors inhibitors. Ann Oncol 2005; 16 (Suppl 4): iv61-iv68.
14. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009; 45: 574-578.
15. Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin resistant stage IV head and neck cancer patients. Acta Otolaryngol 2008; 31: 1-6.
16. Hitt R, Irigoyen S, Nuñez J, et al. Phase II study of combination cetuximab and paclitaxel in patients with metastatic/ recurrent squamous cell carcinoma of head and neck. Spanish Head and Neck Cancer Group (TTCC). Proc ASCO 2007: Abstr 6012.
17. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
18. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001; 91: 541-547.